Background The risk of stroke varies considerably across different groups of patients with
atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is associated with an increased …

Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the American
College of Chest Physicians Evidence-Based Guidelines Clinical Practice Guidelines (8th …

Atrial fibrillation (AF) is an important risk factor for stroke. According to a pooled analysis of
controlled clinical trials with warfarin, anticoagulation therapy reduces stroke risk by 62 …

Purpose: To characterize the efficacy and safety of anticoagulants and antiplatelet agents for
prevention of stroke in patients with atrial fibrillation. Data Sources: Randomized trials …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the Seventh
ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based …

The risk of stroke in atrial fibrillation (AF) needs to be assessed in each patient to determine
the clinical and cost-effectiveness of thromboprophylaxis, with the aim of appropriate use of …

Background: Atrial fibrillation is a strong independent risk factor for stroke. Purpose: To
characterize the efficacy and safety of antithrombotic agents for stroke prevention in patients …

Background Antithrombotic therapy reduces stroke, embolism and mortality in patients with
atrial fibrillation (AF); however, meta-analyses have focused on pairwise comparisons of …

ContextWarfarin has been shown to be highly efficacious for preventing thromboembolism in
atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is …